A year later, Shengxiang With its relat parties in a joint venture, Hunan Shengwei Sumin Biotechnology Co., Ltd., to further focus on the field of rapid drug sensitivity testing.
In addition, Shengxiang Bio has also introduc former senior executives of international giants, establish
industrial funds, and taken a series of measures to enhance portuguese timor email list 100000 contact leads its innovation capabilities and expand its
industrial layout, in order to achieve “second entrepreneurship” and maintain its highspe growth momentum.
With RMB 800 million invested in growth hormone, Shengxiang Biopharma acquires Zhongshan Haiji
16
2025-01-13
The first cross-border acquisition order of the year has arrived
According to the latest public announcement of Shengxiang Bio, the company plans to acquire 100%
equity of Zhongshan Weiming Haiji Biotechnology Co., Ltd. (referred to as “Zhongshan Haiji”) for RMB
807.5 million in cash. After the transaction is completed, Zhongshan Haiji will become a wholly-owned subsidiary of the company.
The company stated that the acquisition was intended the way to greatness to actively implement the country’s call for
children’s health management and promote long-term balanced population development.
At the same time, it would utilize the company’s business advantages in in vitro diagnostics and
Zhongshan Haiji’s business advantages in growth hormone to promote the company’s comprehensive
strategic layout of “integrated diagnosis and treatment” and enhance the company’s profitability.
However, competition in the growth hormone market is becoming increasingly fierce
Some institutions predict that the global market size will be approximately US$3.4 billion in 2022,
with a compound annual growth rate of approximately liechtenstein number 8.1%, and is expected to reach a market size of
US$7.3 billion by 2032. The Chinese market is also showing a rapid growth trend. In 2021, the scale of
China’s growth hormone market exceeded 10 billion yuan, and exceeded 12 billion yuan in 2022.
As parents pay more attention to their children’s dwarfism and medical technology continues to
advance, it is expected that the penetration rate of growth hormone will increase to about 10% in the
next 5-10 years, which will bring huge market growth space for the growth hormone industry A year later, Shengxiang.